> Materia Medica Holding NPF, LLC (Moscow)

This information cannot be used for self-medication!
Consultation with a specialist is required!

The private pharmaceutical company Materia Medica Holding, founded in 1992, produces more than 20 traditional and innovative homeopathic medicines. The created drugs are the fruit of many years of research work by the company’s team, as well as cooperation with national and foreign research institutions.

The production complex, located in Chelyabinsk, was designed and built according to Good Manufacturing Practice (GMP) standards. It is equipped with modern equipment from the best suppliers and has two control laboratories - analytical and microbiological, equipped in accordance with the requirements of Good Laboratory Practice (GLP).

The products of Materia Medica Holding, already well known in Russia and the CIS countries, continue to gain popularity, entering the European market and the markets of Asian countries.

The Materia Medica Holding company produces:

• non-hormonal homeopathic remedy Klimaksan in granules and tablets, softening the symptoms of menopause in women;


• sedative drug Calm down in granules and tablets, eliminating symptoms of irritability and nervousness;


• symptomatic homeopathic remedy Agri for adults and children, eliminating fever and inflammation during colds;


• tablet homeopathic medicine Avia-More, eliminating the symptoms of motion sickness in transport by increasing the resistance of the vestibular apparatus;


• Vernison– a product in granules for the correction of sleep disturbances;


• drug with cardiotonic and sedative effects CardioICA in granules for the treatment of functional heart disorders;


• Mlekoin in granules – a means for correcting reduced breast milk production in nursing mothers;


• homeopathic tablets Feminalgin, eliminating or weakening the manifestations of premenstrual syndrome;


• a remedy with analgesic and anti-inflammatory effects for sore throat Faringomed


• agents that stimulate immune defense against respiratory viruses, Anaferon® And Anaferon® for children in tablets;


• homeopathic remedy with analgesic effect Artrofon® in tablets, inhibiting the production of active mediators of inflammatory processes in the joints;


• drug with anti-edematous properties Afalou® in the form of tablets for the symptomatic treatment of prostate diseases;


• agent with a multifactorial mechanism of action Brizantine® in tablets, eliminating withdrawal symptoms when quitting smoking;


• means of combating excess weight Dietressu® And Diet-Comfort in tablets that dull the feeling of hunger and reduce appetite;


• innovative nootropic drug Divazu® in tablets for the treatment of cerebral circulatory disorders;


• erectile function regulator Impazu® in tablets, enhancing potency regardless of the cause of its occurrence;


• a drug with anti-inflammatory and hypokinetic (slowing down motility) effects Kolofort® in tablets – the drug of choice in the treatment of irritable bowel syndrome;


• homeopathic remedies Proprothene-100® in drops and tablets and Anti-e in drops for the treatment of alcohol dependence;


• sedatives Tenoten® And Tenoten® for children in tablets to relieve anxiety, irritability, nervousness;


• a product with antiviral and antihistamine properties Ergoferon® in tablets for accelerated treatment of respiratory viral infections;


• lozenges Nikomel®, weakening dependence on nicotine;


• homeopathic remedy To the Poets® in tablets, stimulating the formation of red blood cells in anemia;


• antiallergic agent Progistam® in lozenges;


• homeopathic antihypertensive remedy Kardosten® in lozenges, effective in the treatment of arterial hypertension;


• antiulcer agent Epigam® tablets, which suppresses the production of hydrochloric acid in the stomach and helps speed up the healing process;


• excipient granulated sugar for the production of homeopathic remedies in the form of granules.

Open data from the Internet: LLC NPF Materia-Medica Holding, authorized capital of 100 thousand rubles ($1,500, a “huge” amount for a pharmaceutical company).

The guys have been pumping money out of thin air for over 20 years. Well done, what else can I say, I am sincerely jealous.

However, you are not obligated to pay them at all.

The author of the site is a strict adherent of evidence-based medicine (all kinds of evidence levels I, II, III, IV, find them on the Internet if you are interested) and when studying medications, he stubbornly looks for these numbers in the information about the drugs, so as not to recommend outright bullshit to readers.

So, let's get to know the company by exploring the official website (quotes copied November 23, 2016).

History page:

"Founded in 1992, Materia Medica Holding launched the first mass production in Russia HOMEOPATHIC drugs and made them available to a wide range of consumers."

"By the end of the 90s, the company's portfolio already included 10 HOMEOPATHIC drugs from different (Oh how!) pharmacological groups. Thanks to its high safety profile combined with efficiency, HOMEOPATHIC The drugs quickly gained the trust of doctors and patients."

I quote so that it is clear where the legs come from and why the production was created. Keyword HOMEOPATHY(that is, diluting the supposedly active substances billions of times, so that not a single molecule of “drug” remains in the tablet).

"About" page:

"Research in accordance with the requirements of GLP (Good Laboratory Practice) and GCP (Good Clinical Practice) guarantees a high profile SECURITY drugs. In 2015-2016, Materia Medica conducted preclinical studies at 29 sites and clinical studies at 182 sites."

About SAFETY written, but about EFFICIENCY not a word, and nothing about any research with classes of evidence either. That is, from the official website of the company it is clear that the homeopathic office EFFICIENCY I’m not fundamentally puzzled by my medications. Draw conclusions.

And the safety of, for example, tap water is also not bad, but the price is cheaper.

Materia Medica preparations on the international pharmaceutical website Vidal

Go to http://www.vidal.ru/drugs/firm/961. Please note that before 2010, medicines were labeled as “homeopathic”, and after 2010 the word “homeopathy” disappears from the descriptions.

Apparently, then the company’s marketers realized that you couldn’t get very far with homeopathy, and began to tell the illiterate population that they produced incredibly effective AFFINITY PURIFIED ANTIBODIES to any regulatory substances. There are a lot of obscure words in the new rewritten instructions, fiction “inspires”, advertising on TV is broadcast, sales are going on.

However. ANTIBODIES ARE PROTEINS, all of the company's "antibodies" are produced in tablets and taken orally. But that's the problem, that's it PROTEINS in the gastrointestinal tract BREAKDOWN INTO REGULAR FOOD AMINO ACIDS and there can be no talk of any therapeutic effect of the protein (http://meduniver.com/Medical/Physiology/1154.html).

Besides, NONE the company's drug is not positioned in the international classification of ATC drugs, NONE the drug does not have an international nonproprietary name (INN). That is, this is a small-town Russian office for buyers with big ears that are convenient for hanging noodles on.

By the way, since 2016, the US Food and Drug Administration (FDA) has obliged homeopathy manufacturers to indicate the truth on the label (https://hightech.fm/2016/11/18/homeopathy). I believe this will not happen soon in our country.

HoldingMateria Medica- Russian private pharmaceutical manufacturing company, founded in 1992, produces and sells more than 20 brands on the OTC market in Russia and the CIS, and has its own research bases.

Source: http://www.materiamedica.ru

Materia Medica is among the TOP 10 Russian and foreign pharmaceutical companies in the Russian OTC market.

Research activities

Materia Medica is engaged in fundamental research in the field of ultra-low dose pharmacology

Materia Medica's scientific and clinical research divisions collaborate with leading Russian and foreign research institutes and institutions to conduct joint research and obtain new experimental and clinical data. Among them:

• Center for Interferon and Cytokines, State Research Institute of Epidemiology and Microbiology named after. N.F. Gamaleyi RAMS (Moscow)
• Research Institute of Influenza Northwestern Branch of the Russian Academy of Medical Sciences (St. Petersburg)
• Central Research Institute of Epidemiology of Rospotrebnadzor (Moscow)
• First Moscow State Medical University named after. THEM. Sechenov (Moscow)
• Russian National Research Medical University named after N. I. Pirogov (Moscow)
• Antivirus Research Institute (USA)
• L. Pasteur Institute (France).

Production

The Materia Medica plant has its own infrastructure to ensure production and is equipped with the latest high-tech equipment (L.B.Bohle, HÜTTLIN, Korsch, CAM).

Product quality is guaranteed by GMP certificates.

Suppliers of active pharmaceutical ingredients to Materia Medica are specialized, including immuno-biological, enterprises in Scotland, Switzerland and the Netherlands.

The Materia Medica production complex is located in Chelyabinsk. The company is one of the largest employers in this region.

Scientific director of Materia Medica Holding Oleg Epshtein explained the principle of action of release-active drugs

Scientific director of Materia Medica Holding Oleg Epshtein explained the principle of action of release-active drugs

Oleg Epshtein, Doctor of Medical Sciences, Corresponding Member of the Russian Academy of Sciences, Scientific Director of NPF Materia Medica Holding LLC, answers the questions of the Rossiyskaya Gazeta correspondent.

Please tell us about your discovery, which was called release activity. How did you come to it?

After graduating from medical school, I worked as a psychiatrist for several years. I would like to note that I loved my work, and was especially interested in the new trends in psychopharmacology at that time. Like most of my colleagues, I knew little about alternative medicine, including homeopathy, and therefore had a negative attitude towards it. However, after perestroika, the opportunity arose to become familiar with the basics of this unusual direction and to take official homeopathy training courses that appeared for the first time. I did not become a professional homeopath, but the very method of treatment using small doses interested me from a scientific point of view.

Homeopathy, despite more than two centuries of experience in this method, is too complex to use - for successful treatment, a homeopathic doctor must have very high qualifications. Classical homeopathy is an individual therapy and, as a result, cannot be part of modern evidence-based medicine. But most importantly, I began to understand that the principle of similarity, on which classical homeopathy is based, cannot explain all the effects that drugs cause in high dilutions.

For example, in the 70-80s of the last century, without any connection with homeopathy, famous scientists - chemists and biologists in many countries, including Russia (academician I.P. Ashmarin, professor E.B. Burlakova and many others), in the process of conducting biological experiments, noticed that various drugs, diluted to such an extent that they theoretically no longer contain molecules of the original substance, are capable of exerting effects in the body at the molecular level.

A fairly large array of experimental results on the biological effects of drugs in high dilutions (small doses) has been accumulated, but these works have not led to the creation of new drugs. Firstly, I believe that scientists have been held back by their critical attitude towards homeopathy. Secondly, there was no breakthrough, unambiguous understanding of the mechanism of the new phenomenon.

Gradually I came to the idea that the answer lies in the very process of preparing high dilutions, which outwardly represents a simple sequential, repeated reduction in the concentration of the original substance. I suggested that, in fact, this is an extremely complex technological process, during which a set of new physicochemical and biological properties, called release activity, appears (releases) in the resulting product.

The first step towards solving the mystery of high dilutions was taken in 1995, when we, together with well-known Russian research institutes, organized a series of experiments: animals were injected with toxic or subtoxic doses of conventional pharmacological drugs (prednisolone, diclofenac, phenazepam, haloperidol, cyclophosphamide, aspirin and etc.) and at the same time a high dilution (low dose) of the same drug. It turned out that in all cases a “small” dose had a modifying (to put it simply, catalytic) effect, which was manifested by enhancing the effect of the pharmacological drug and reducing its toxicity. Subsequently, we ourselves and a number of scientists from fundamental physical institutes established that high dilutions can have a modifying effect on the original substance outside the body.

The modifying properties of a technologically processed carrier, which we discovered for the first time, are an extremely useful practical discovery that can be used both in medicine and in various fields of technology, including nanotechnology. When studying high dilutions, we collaborate with physicists, including theorists. The famous theoretical physicist S. Odintsov believes that the nature of high dilutions remains unstudied, but is relevant, since the description of such liquids can lead to new fundamental discoveries.

For pharmacology, of course, first of all, the molecular mechanisms of action of small doses are important, which have now been studied in sufficient detail.

Are there other scientific groups developing the same ideas, in Russia or abroad?

Our studies have shown that the new possibilities we have discovered in the technology for obtaining high dilutions open up the prospect of creating fundamentally new effective and safe medicines. I was well aware that new drugs needed to be developed ourselves, since no one in Russia or abroad was working on similar topics. As a result, we created on our own a full-fledged research and production enterprise LLC "NPF "MATERIA MEDICA HOLDING" with a full cycle: from the idea to the finished dosage forms. Naturally, in order to organize such production, I had to do a lot of self-education, immerse myself in different areas of knowledge : pharmacology, biology, immunology, pathophysiology. Over time, I defended my PhD and doctoral dissertations under the guidance of my teachers - famous scientists, academicians - pharmacologist E.D. Goldberg and neurobiologist M.B. - correspondents of the Russian Academy of Sciences.

Like many other small companies, we work on a contract basis with specialized laboratories. At first, the necessary experimental work was carried out only in Russia, but gradually the geography expanded: currently we are collaborating with research organizations, universities and institutes in twenty countries, publishing the results obtained in Russian and Western journals. Our own clinical research department with a powerful statistical data processing unit independently conducts a large number of clinical studies, including international ones, in accordance with GCP requirements; all of them are registered on a specialized electronic resource - www.clinicaltrials.gov.

The production of drugs at the plant in Chelyabinsk is carried out in full compliance with national and international requirements for good manufacturing practice (GMP).

As far as we can understand, the drugs you are developing are not homeopathy?

Homeopathy - individual therapy. From a modern point of view, the goal of a homeopathic prescription is to try to cause the body to respond to a drug in a small dose through the immunological mechanisms of individual sensitivity. Our scientific work has essentially allowed us to create a new class of biological drugs. In terms of preparation technology, it is similar to homeopathy, but according to modern principles of application, based on the use of molecular approaches, the possibility of targeted action on biological targets in the body, in terms of effectiveness, and most importantly - the possibility of integration into evidence-based medicine, it is similar to “conventional” pharmacological drugs. Leading drug regulatory agencies in the USA, England, Europe (FDA, MHRA, EMA), with whom we consulted, also believe that our drugs based on low doses of antibodies are biological and not homeopathic.

At some point, the company acquired new drugs that were invented within the company. Please tell us when and how this happened and what kind of medicine it was.

In collaboration with Academician M.B. Stark, and then with specialists from other well-known domestic scientific institutes, we have developed a group of unparalleled drugs based on high dilutions of antibodies - proteins produced by the immune system. The main feature of these agents, which we call release-active antibodies, is their ability to specifically influence target molecules in the body, modifying their physicochemical properties, which leads to a positive change in the nature of the biological processes in which they are involved. This effect is physiological in nature and determines the therapeutic effect of release-active drugs.

Today, release-active drugs are used in various therapeutic areas.

The development of innovative biological drugs based on high dilutions of antibodies, in which famous Russian pharmacologists, physiologists, pharmacists and clinicians participated, was awarded the Russian Government Prize twice - in 2005 and 2006.

We really want to hope that our discovery will continue to be supported at the state level, and that the legal and regulatory issues that inevitably arise during the implementation of any major undertaking will be resolved - for the sake of patients who need safe and highly effective drugs.